In the heart of Montgomery County, Maryland’s premier biotech district there is a 42,000 SF facility with 17,000 SF vacant lab/office suite located at 9900 Medical Center Drive. The newly delivered and available lab space was designed to foster collaboration and learning with an open layout, a welcoming courtyard and an inside common area that is shared with other local tenants. 


Maryland Technology Development Corp. has tapped an interim leader for the Maryland Venture Fund, which was the subject of a damaging state audit report and subsequent reform legislation earlier this year.

Elizabeth Good Mazhari has been named the interim managing director of TEDCO’s Maryland Venture Fund or MVF. The appointment comes as TEDCO is finalizing new governing regulations that it hopes will meet legislators' expectations of how it should be distributing state funds to Maryland startups. New investments through the MVF have been halted since June, while TEDCO enacts legislative-directed reforms and works to fill executive positions left open by a slew of recent resignations. Former MVF Managing Director Andy Jones announced his departure from TEDCO in May.



Having an MRI scan can be an unpleasant experience. The procedure often involves a patient lying down inside a large tube for at least 30 minutes and being instructed to remain motionless as magnetic and radio waves create detailed pictures of their organs. Many find the machine's loud, clanging noises unnerving and are left feeling panicky and claustrophobic.

Image: Johns Hopkins doctoral student Puyang Wang -


SHANGHAI, Dec. 11, 2019 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today opened an innovation and customer support center in Shanghai, China to support biopharma research and technology development in the region. Avantor now has nine innovation centers worldwide.


bio pharma

2019 saw a new record set for a list price of a prescription therapy—$2.1 million for the gene therapy Zolgensma® launched by AxeVis, a Novartis Company—and resulting renewed concerns over the price of treatments and whether politicos will ever be able to address the issue as the nation’s presidential election campaign season heats up.



The recycled rhetoric questioning the role of the biopharmaceutical industry in the discovery and development of innovative medicines continues to rear its ugly head in the ongoing discussion about the high cost of health care and what to do about it. But, for patients with unmet medical needs, this continued skepticism is merely a distraction. 

Most patients understand that their hope for future cures relies on the work that biopharma does to translate basic science into deliverable treatments and medicines. That understanding is backed by facts. 



Nearly 400 biotech leaders from across the Biohealth Capital Region (BHCR) gathered recently in Bethesda, Maryland at the Bio Innovation Conference, hosted by Maryland Life Sciences (MDLS), a division of the Maryland Tech Council. The event focused on advancements and opportunities for Maryland cell and gene therapy companies and why Maryland is becoming the number one location of choice for growing biotech companies. However, it was the afternoon keynote featuring JLABS @Washintgon, DC’s Michelle McMurry-Heath, MD, PhD, that caused a buzz in the crowd. 



Four experts in life sciences and digital health development, commercialization, and investment peered into their proverbial crystal balls to offer insights on “What’s Hot in Life Sciences: A Look at the 2019 Trends and What’s on the Horizon for 2020”—the title of a panel discussion held recently at JLABS@NYC in SoHo . . .



Merger and acquisitions (M&A) activity within the healthcare industry heightened last year, according to recent research data and this could feed into gains for M&A and healthcare-focused ETFs for traders sensing an opportunity.

“The U.S. healthcare market saw a 14.4 percent increase in mergers and acquisitions from 2017-2018, fueled by soaring domestic venture capital investment – an all-time high of $130.9 billion invested in U.S.-based startups in 2018 alone,” a press release by Sage Growth Partners said. “Compounding the pace and complexity of deal flow are sweeping industry trends ranging from managing and measuring health outcomes to reducing the overall cost of care.”



31 Maryland biology colleges offer certificates, associate's, bachelor's, master's, and doctoral degrees in biological engineering and technology, physiology and anatomical sciences, and zoology and animal biology and 9 other programs.

The best biology programs in Maryland are offered by Johns Hopkins University. This biology college offers an excellent quality programs - five stars for curriculum and five stars for teaching.



Pasadena-based real estate investment trust (REIT) Alexandria Real Estate Equities, Inc. has launched a first-of-its-kind consortium to catalyze advanced biological innovation and manufacturing.

As a founding member of this consortium of top-tier academic institutions, research hospitals and life science industry partners, Alexandria will have a seat on the board of directors alongside Harvard University, the Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies and GE Healthcare Life Sciences, the company said in a statement.


Scott Gottlieb official portrait Scott Gottlieb Wikipedia

Trump‘s choice to lead the Food and Drug Administration has ties to both Wall Street and drug makers

A conservative doctor-turned-pundit with deep ties to Wall Street and the pharmaceutical industry is President Donald Trump‘s pick to lead the Food and Drug Administration.

Dr Scott Gottlieb, 44, would be tasked with Trump‘s goal of cutting red tape at the FDA, which regulates everything from pharmaceuticals to seafood to electronic cigarettes. 


Us Capitol Building Washington Dc Free photo on Pixabay

A key part of president Donald Trump’s strategy to cut drug prices was to attack global “freeloading” for pharmaceuticals, targeting countries pushing back against pharma companies trying to charge higher US-level prices for their products.

But in trade negotiations with Canada and Mexico, it looks like that the Trump administration has not followed through on the strong rhetoric set out in his drug pricing strategy published last year.

According to press reports Trump’s negotiating team have agreed to scrap provisions on exclusivity of biologics, allowing each country to decide when the patent protection period expires on biologics.



Xconomy New York —  Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at the earliest stages with a new $210 million venture capital fund.

The Perceptive Xontogeny Venture Fund (PXV) is led by Chris Garabedian (pictured above, center), a veteran biotech executive whose experience includes stops at Gilead Sciences (NASDAQ: GILD), Celgene, and Sarepta Therapeutics (NASDAQ: SRPT). He’s currently the chairman and CEO of Xontogeny, a Boston-based life sciences accelerator.



Elizabeth is the interim Managing Director of TEDCO’s MVF.  She brings more than 25 years of academic, government, and private sector experience in product development, technology commercialization and venture management experience to the team.  Prior to joining TEDCO, she served as President of Transition Health Ventures, a consulting firm specializing in serving the needs of the innovation community and the healthcare and life science startup companies within it.  Elizabeth also spent more than 8 years in academic venturing roles JHU and UMB.  Additionally, Elizabeth previously served as Managing Director of the MVF (2004-2006) in addition to progressively senior roles with the Fund between 2000-2004.  She started her career in San Diego in venture-backed medtech startups in product development roles after completing her Masters in Bioengineering from UC San Diego, and BSE from Duke University and Biomedical and Electrical Engineering.


BioTalk Skyscraper Chuck and Rich

Chuck Morton, Partner, Venable, LLP, joins BioTalk host Rich Bendis to discuss the local entrepreneurial and business ecosystem, regionalism, and the BioHealth Capital Region

Chuck Morton is co-chair of Venable's Corporate Group. Chuck is recognized for his abilities in guiding financing, mergers and acquisitions (M&A), and other transactions involving middle-market companies. Chuck assists lenders, investors, and entrepreneurs as they create, build, and buy or sell businesses, primarily in the healthcare, technology, and consumer products industries. He regularly acts on behalf of private equity groups and banks. Chuck currently serves as the Secretary on the BioHealth Innovation Board of Directors.

 Listen now on Apple Podcasts, Google Podcasts, and TuneIn


Ben Wu, the deputy secretary of the Maryland Department of Commerce, has been named as the new CEO for the Montgomery County Economic Development Corporation.

MCEDC is a public-private economic development nonprofit for the county.

The Montgomery County agency’s board of directors announced the appointment in a press release on Wednesday afternoon. Wu’s first day is Dec. 18.

Image: Ben Wu, Maryland's deputy commerce secretary, has been named as the new CEO for the Montgomery County Economic Development Corporation. PHOTO FROM MONTGOMERY COUNTY ECONOMIC DEVELOPMENT CORPORATION

Jay A. Perman

Jay A. Perman will take over as chancellor of the University System of Maryland in January as Robert L. Caret steps down six months earlier than planned.

Caret had decided not to seek another five-year contract, and the system’s Board of Regents announced it had chosen Perman, the University of Maryland, Baltimore President, to succeed Caret in June.

But on Friday, the Board of Regents announced that University of Maryland, Baltimore’s provost and executive vice president, Bruce Jarrell, will take over as the interim president of the university early next year. In a letter to the University of Maryland, Baltimore community, Perman said that the Regents “has set my start date” as Jan. 6.


emmes logo

ROCKVILLE, Md., Dec. 2, 2019 /PRNewswire/ -- Emmes today announced that it is part of a team of medical centers, universities and private industry supporting the development of a "universal influenza vaccine" that could provide longer-lasting protection than current vaccines and combat a wider variety of influenza viruses.


MaxCyte Logo

Gaithersburg, MD and Cambridge, MA – December 4, 2019: MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement. Under the agreement, KSQ gains rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of KSQ’s engineered tumor-infiltrating lymphocyte (eTIL™) programs, which the company is developing for the treatment of PD-1 refractory solid tumors.


Johns Hopkins APL Takes 3D Printing of Electronic Parts to the Next Level

Newswise — The rise of additive manufacturing – or as it's more commonly known, 3D printing – has enabled the rapid production of complex parts across many domains. As the techniques have become more refined, the semiconductor industry has taken note. But until recently, no one's been able to form single-crystal materials – the building block of semiconductors – with traditional additive manufacturing processes.

Image: Johns Hopkins APL Takes 3D Printing of Electronic Parts to the Next Level


In May of 2018 Kite Pharma, a Gilead Company, announced the opening of a new Neo Antigen Facility in Gaithersburg, MD. Less than one year later in April of 2019, the company, announced that it was building a new biomanufacturing facility on a 20-acre site in Frederick, MD. Since then, Kite has been diligently working to build a world-class leadership team at both sites to achieve an important mission.



Full-house, standing room only at our 'Launching Life Sciences Innovation in Baltimore' event co-hosted by LifeBridge Health and The LaunchPort at Rye Street Tavern. Thank you to MARYLAND BUSINESS INCUBATION ASSOCIATION and Weller Development for your support.



A biotech startup that’s backed by Silicon Valley’s well-known Y Combinator accelerator has ties to Baltimore: GEn1E Lifesciences is working to commercialize a treatment for inflammatory and age-related diseases that was developed at the University of Maryland, Baltimore, and is partnering with a Baltimore-based startup that also grew out of UMB collaboration.

Image: Dr. Ritu Lal is CEO of GEn1E Lifesciences. (Courtesy photo)

Artificial Intelligence Brain Free image on Pixabay

A Maryland-based biotechnology firm seems to have solved a puzzling issue for drug targeting and delivery that may usher in an era of gene therapies for neurological disorders. Rockville, Maryland’s REGENXBIO’s NAV Technology Platform provides the ability to treat neurological disorders by targeting specific disease-related genes or gene products. Their patented technology glides across the blood-brain barrier (BBB) without triggering the patient’s immune system as with unengineered adeno-associated virus (AAV)-derived vectors, providing localized gene delivery with few side effects.


Melissa Fassbender

Xconomy Boston —  After joining AstraZeneca’s Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and cardiovascular diseases.

Under the collaboration, expected to last multiple years, Gatehouse will use its sRNAlytics platform to identify small RNA (sRNA) signatures, which the company says help in diagnosing and subtyping diseases from human samples. Financial terms were not disclosed.


Hogan administration official Benjamin Wu tapped to lead Montgomery County s economic development efforts Washington Business Journal

Montgomery County has a new top economic development official: Benjamin Wu, formerly a top adviser to Maryland Gov. Larry Hogan.

Wu will take over as the president and CEO of the Montgomery County Economic Development Corporation Dec. 18, according to a news release. The group has been searching for a new leader ever since David Petr, its inaugural CEO, left this fall.

Image: Benjamin Wu will take over as the new head of the Montgomery County Economic Development Corporation. DBED


This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative ( through the Office of the NIH Director, Office of Strategic Coordination ( All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Dental and Craniofacial Research (NIDCR) on behalf of the NIH.


Cerecor Logo

ROCKVILLE, Md., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan and rare diseases, as well as neurology announced today it has entered into a definitive merger agreement to acquire Aevi Genomic Medicine (NASDAQ: GNMX) in an all-stock transaction valued at approximately $16.1 million at closing, plus contingent value rights, or CVRs, for up to an additional $6.5 million in subsequent milestone payments on clinical or regulatory successes, or both.  Additionally, the Company is exploring strategic alternatives for its neurological assets as well as its one commercialized product Millipred®.


EMMes Developed A Universal Influenza Vaccine For The National Institute of Allergy and Infectious Diseases Ask Health News

EMMes has announced the development of a vaccine for the flu that is “universal influenza vaccine”.  EMMes is the part of a team including medical centers, private industry, and universities that support the development of a vaccine. The vaccine provides protection for a long time as compared to currently available vaccines. Moreover, it is capable to fight against a wide range and variety of influenza. The news was announced in ROCKVILLE on Dec 2, 2019.


Your Invited to a special CEO Talks event to hear from these serial Biotech Entrepreneurs


We would like to invite you to a special event to join other industry leaders and peers to celebrate a year of growth within our entrepreneurial ecosystem and the greater Biohealth Capital Region.

Several of the region's top startup executives will participate in an engaging discussion and share the lessons they have learned along their journeys in building their past and current companies.